Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5281752
Max Phase: Preclinical
Molecular Formula: C21H19NO3
Molecular Weight: 333.39
Associated Items:
ID: ALA5281752
Max Phase: Preclinical
Molecular Formula: C21H19NO3
Molecular Weight: 333.39
Associated Items:
Canonical SMILES: O=C1/C(=C/c2ccc(N3CCCC3)cc2)Cc2cc3c(cc21)OCO3
Standard InChI: InChI=1S/C21H19NO3/c23-21-16(10-15-11-19-20(12-18(15)21)25-13-24-19)9-14-3-5-17(6-4-14)22-7-1-2-8-22/h3-6,9,11-12H,1-2,7-8,10,13H2/b16-9+
Standard InChI Key: MFYJMHRJESJTBE-CXUHLZMHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 333.39 | Molecular Weight (Monoisotopic): 333.1365 | AlogP: 3.84 | #Rotatable Bonds: 2 |
Polar Surface Area: 38.77 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 4.83 | CX LogP: 4.03 | CX LogD: 4.03 |
Aromatic Rings: 2 | Heavy Atoms: 25 | QED Weighted: 0.78 | Np Likeness Score: -0.31 |
1. Altıntop MD, Özdemir A, Temel HE, Demir Cevizlidere B, Sever B, Kaplancıklı ZA, Akalın Çiftçi G.. (2022) Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer., 244 [PMID:36270087] [10.1016/j.ejmech.2022.114851] |
Source(1):